Full-Time
Accounting Manager
eGenesis
51-200 employees
Genetically engineered porcine kidneys for humans
Compensation Overview
$120k - $154k/yr
Cambridge, MA, USA
Hybrid
Hybrid role; some on-site days at Cambridge, Massachusetts office.
Bachelor's
 Accounting (1) |
|---|
Get referred to eGenesis
See people who can refer or advise you
- Bachelor’s degree in Accounting or Finance required; CPA preferred
- 5+ years of progressive accounting experience, including public accounting and/or industry experience
- Public company accounting experience preferred, including demonstrated ownership of monthly close process under public company reporting timelines
- Biotech or life sciences industry experience required; familiarity with clinical-stage accounting (CRO accrual methodology, collaboration agreement) strongly preferred
- Hands-on proficiency with NetSuite required
- Excellent analytical, organizational, and communication skills, with strong attention to detail
- Ability to work independently, prioritize, and adapt in a fast-changing environment
- Own the end-to-end financial close process, including general ledger, accounts payables, and accruals, delivering accurate and timely monthly, quarterly, and annual financial statements in compliance with U.S. GAAP
- Account for R&D expenses, clinical trial accruals and prepaids, and CRO vendor arrangements, coordinating closely with clinical and operations teams to estimate accruals
- Help design, implement, and maintain internal controls over financial reporting (ICFR) in preparation for SOX compliance and public-company requirements
- Support preparation and maintenance of financial statements and supporting schedules, ensuring disclosures are accurate, complete, and audit-ready
- Manager Senior Accountant, fostering a high-performance team environment
- Design, implement, and maintain a robust internal control environment appropriate for a company operating under public company accounting standards
- Manage NetSuite as the system of record, partnering with FP&A on chart of accounts governance, reporting configuration, and process improvements
- CPA preferred
- Public company accounting experience preferred
- Biotech or life sciences industry experience strongly preferred
- Familiarity with clinical-stage accounting (CRO accrual methodology, collaboration agreement) strongly preferred
eGenesis develops genetically engineered porcine (pig) kidneys and other organs that are compatible with human bodies, aiming to address the organ shortage by enabling transplantations into humans. Its product is created by editing pig genes to reduce rejection and improve compatibility, producing HuCo™ (Human Compatible) organs and cells that can be transplanted by healthcare providers. Unlike many biotech firms that focus on synthetic tissues or other approaches, eGenesis concentrates on xenotransplantation—using animal organs engineered to be accepted by the human immune system—for use in patients awaiting transplants. The company’s goal is to save lives and improve quality of life by expanding the supply of transplantable organs and reducing wait times for patients in need.
Company Size
51-200
Company Stage
N/A
Total Funding
$470M
Headquarters
Cambridge, Massachusetts
Founded
2015
Get referred to eGenesis
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 brought CFO Glenn Vraniak and CCO Jennifer Bergheiser for commercialization.
- RESTORE launches in 2027 with up to 33 kidney patients, expanding beyond expanded access.
- NATCO Pharma raised investment to $22 million, signaling external validation and runway.
What critics are saying
- Tim Andrews' pig kidney failed after nine months from thrombotic microangiopathy in September 2026.
- eGenesis still depends on expanded access until RESTORE starts, leaving commercialization unproven.
- A serious RESTORE death would freeze FDA momentum and likely cripple investor confidence.
What makes eGenesis unique
- eGenesis uses 69 edits, including 59 viral inactivations, exceeding United Therapeutics' 10 edits.
- Its pig kidneys bridged two patients to human transplants, including Tim Andrews.
- FDA cleared eGenesis kidney and liver programs, giving it a multi-program xenotransplantation platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Conference Attendance Budget
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 0%Genetically modified pig kidneys have kept two kidney failure patients alive long enough to receive human organ transplants for the first time, according to biotech company EGenesis. Tim Andrews, a 66-year-old from New Hampshire, received a modified pig kidney in January 2025. The organ functioned for about nine months before failing, but kept him stable enough to survive until a human kidney became available. Andrews, who had been told he would likely die before receiving a transplant, felt immediate improvement after the pig kidney procedure. He could walk around freely without dialysis and regained his energy. EGenesis says a second patient also received a pig kidney that served as a successful bridge to a human transplant. The company hopes to make the organs widely available within approximately four years, pending further testing.
NATCO Pharma Limited has increased its investment in eGenesis, Inc., a biotechnology company developing transplantable organs through genome engineering. The Indian pharmaceutical firm is adding $14 million to its stake, bringing its total investment to $22 million. The additional funding comes through NATCO Pharma (Canada) Inc. ($9.5 million) and NATCO Pharma South Africa Proprietary Limited ($4.5 million) via convertible promissory notes. This follows an initial $8 million investment in preferred stock made in 2024. eGenesis, based in Cambridge, Massachusetts, uses its EGEN Platform to address organ shortages through genetic engineering. The company is developing programmes for kidney, liver, and heart transplants. In March 2024, eGenesis performed the world's first porcine kidney transplant in a living patient, authorised by the US FDA.
eGenesis appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer. Provided by Business Wire Jun 22, 2026, 5:00:00 AM Leadership additions support company's advancement through the next phase of growth eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation, today announced the appointments of Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer. Glenn S. Vraniak, Chief Financial Officer, eGenesis The appointments come as eGenesis advances in clinical studies across multiple programs, including EGEN-2784 for kidney failure and a program for acute-on-chronic liver failure, positioning the company for its next phase of growth. "eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization," said Mike Curtis, Ph.D., Chief Executive Officer, eGenesis. "Glenn brings deep expertise and proven leadership across finance, capital formation, and business development and we are thrilled to have him join the team to help drive the next phase of growth for the company." Mr. Vraniak brings more than two decades of executive leadership experience across biotechnology, medical technology and specialty pharmaceuticals, with a track record of leading capital raising initiatives, IPOs, strategic transactions and company-building initiatives. Most recently, he served as Chief Financial Officer of Inversago Pharma, where he helped lead the company's growth strategy, financing activities and eventual acquisition by Novo Nordisk in a transaction valued at approximately $1.1 billion. Prior to Inversago, he served as CFO of Evaxion Biotech, Valeo Detection Systems and electroCore. He also served on the Board of Directors of Apollomics Inc, where he chaired the Audit Committee. Throughout his career, Mr. Vraniak has helped raise hundreds of millions of dollars in private and public capital, led IPO processes and supported strategic transactions across both public and private companies. Most recently, at Inversago, he completed a $70 million Series C financing, prepared the company for a potential IPO and played a key role in negotiating its acquisition by Novo Nordisk. "eGenesis has built one of the most innovative platforms in biotechnology and is addressing one of the largest unmet needs in medicine," said Vraniak. "The opportunity to revolutionize the treatment of organ failure and potentially save countless lives is incredibly compelling. I look forward to working alongside this talented team as we advance our clinical programs, strengthen our operational capabilities and position the company for long-term success." Jennifer Bergheiser has been promoted to Chief Commercial Officer after serving as Chief Business Officer at the company since 2022. Ms. Bergheiser brings more than 25 years of experience across biopharmaceuticals, biotechnology, private equity and strategy consulting. Her career has included leadership roles spanning product strategy, commercialization planning, business development and market access. She has extensive experience supporting new product planning and commercialization efforts across multiple therapeutic areas and new modalities, including early brand and commercial strategy for blockbuster biologic therapies such as Stelara(R). In her new role, Ms. Bergheiser will lead product and market development activities for eGenesis' lead kidney program, EGEN-2784, as well as the company's broader pipeline. She will oversee product management, market access, government affairs, patient advocacy and channel strategy as eGenesis prepares for future commercialization and the transformation of the treatment of organ failure enabled by expanded organ supply. "Jen has a proven track record of building and scaling high-performing teams at eGenesis," said Curtis. "She has led key functions across G&A while driving our new product planning efforts over the past several years. We look forward to her continued leadership as we begin laying the foundation for commercialization." "The shortage of organs for transplant is a public health crisis, exacting a staggering toll on patients, families, clinicians and healthcare systems," said Bergheiser. "The opportunity to lead eGenesis' efforts in preparing the market, and our game-changing product portfolio, for commercialization is unmatched. I look forward to partnering with stakeholders across the healthcare landscape to help define a new category of medicine and enable access to a novel and life-saving treatment option for people whose lives have been put on hold by organ failure." About eGenesis eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered, porcine-derived kidney product, is the Company's lead program for patients with kidney failure. The Company has received FDA clearance to conduct clinical studies across its kidney and liver programs. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
eGenesis to participate at BIO International Convention 2026 panel on the future of xenotransplantation. June 18, 2026 CEO & President Mike Curtis joins industry leaders to discuss the clinical progress and potential of xenotransplantation to address the global organ shortage. CAMBRIDGE, Mass. - (BUSINESS WIRE)-eGenesis, a biotechnology company developing human-compatible organs for transplantation, today announced that Michael Curtis, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2026 titled "Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage." As xenotransplantation advances from scientific possibility to clinical reality, the panel will examine the latest progress in gene-edited organ transplantation, advances in genome engineering, and the path toward broader clinical adoption. Session Details Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage Date: Monday, June 22, 2026 Time: 3:00 p.m. - 4:00 p.m. PT Location: Room 24BC, San Diego Convention Center Panelists: * Jonathan Grinstein, Ph.D., North American Editor, Inside Precision Medicine (Moderator) * Cameron Lillie-Liberto, Kidney Disease Patient Advocate * Jesse Roach, M.D., Senior Vice President, Government Relations, National Kidney Foundation * Xiaoxi (Sofie) Wei, Ph.D., CEO & Co-Founder, X-Therma * David Yang, Partner, Lux Capital "Xenotransplantation is at a pivotal moment as decades of innovation in genome engineering and transplantation science have enabled advancement to clinical studies," said Curtis. "I look forward to joining this distinguished group of experts to discuss the progress being made and the potential for xenotransplantation to expand access to lifesaving organ transplantation for patients around the world." Panelists will discuss the scientific, clinical, regulatory, patient, and investment perspectives shaping the future of xenotransplantation, including how advances in gene editing are addressing immune rejection and viral risk, the design of first-in-human studies, and what it will take to scale xenotransplantation into a viable treatment option for patients with organ failure. More than 800,000 Americans and millions worldwide suffer from end stage kidney disease or ESKD. While organ transplantation remains the gold standard for improving survival and quality of life among those living with kidney failure, due to the shortage of organs, only 27,573 kidney transplants were performed in 2025. For those unable to receive a transplant, dialysis remains the only option. The five-year mortality rate associated with dialysis is approximately 60%, higher than the most common cancers. Genetically engineered porcine-derived kidneys offer a promising solution to this crisis. About eGenesis eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company's lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. The company is also advancing programs focused on acute liver failure and heart failure. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. Media Contact
eGenesis to present at 44th Annual J.P. Morgan Healthcare Conference. CAMBRIDGE, Mass. - (BUSINESS WIRE) - eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced that Mike Curtis, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:30 p.m. PT. About eGenesis. eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company's lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. Kimberly Ha eGenesis [email protected]